Clinical Exomes Sequencing to Reporting
Unravelling the Potential of Clinical Sequencing
Professor Charles E. Chappel discusses clinical exome sequencing (CES) as a cutting-edge technique revolutionising our understanding of genetic diseases. This comprehensive guide explores how MGI Sequencers are reshaping research and diagnostics in genomics, focusing on the protein-coding regions of the genome where disease-related variants are most densely packed.
MGI Sequencers: Pioneering Precision in Genomics
Acclaimed for reliability and superior data quality, MGI's range of high-throughput sequencers are integral to various genomic applications, including Clinical Exome Sequencing (CES).
MGI G99 Sequencer
Output: 1 sample / flow cell
Cost-effective and optimized for targeted genomic applications.
MGI DNBSEQ-G400
Output: Up to 50 samples / flow cell
High-throughput performance for large-scale clinical cohorts.
Data Processing and Analysis Workflow
Primary Analysis
Raw sequencing data is processed into FASTQ files via standalone MGI servers and specialized devices.
Secondary Analysis
FASTQ files are converted into VCF files, utilizing MGI's Zitron Pro hardware acceleration for extreme efficiency.
Annotation & Reporting
Integrated software solutions streamline the annotation of VCF files and the generation of final clinical reports.
Customizable Pipelines
Tools allow for seamless integration with third-party or open-source software for flexible, bespoke workflows.
Streamlining Clinical Diagnostics
"Integrating VarSome with MGI sequencers, particularly the T7, enables significantly enhanced clinical diagnostics through superior variant interpretation."
Prof. Charles E. Chappel
"The critical role of high-fidelity sequencing technology is best seen in the complexities of CNV analysis, where accuracy directly impacts patient care."
Dr. Marcela Galvez
"Practical application of the T7 sequencer in clinical environments has proven that throughput does not have to come at the expense of diagnostic accuracy."
Dr. Manuel Delpero
Challenges in CES
Secondary Findings
Requires rigorous informed consent adhering to ACMG guidelines.
Variants of Uncertain Significance (VUS)
Interpreting VUS is complex, requiring periodic reclassification as knowledge evolves.
The Future of Clinical Exome
AI & Machine Learning
Streamlining variant interpretation and identifying patterns missed by traditional methods.
Personalized Medicine
Tailoring treatment plans based on individual genetic makeup to reduce adverse reactions.
Conclusion
Clinical exome sequencing is transforming the landscape of genetic research. The future is not just about technological advances, but about the ethical, collaborative, and patient-centric approach that will define its role in healthcare. By addressing associated challenges, we can unlock the full potential of CES, leading to a new frontier in personalized health outcomes.
Disclaimer: The information provided is for educational and informational purposes only and is not intended for use in diagnostic procedures. MGI products mentioned are for research use only.
Published 1 June 2022
